| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/03/2002 | EP1109536B1 New solid dose form of nanoparticulate naproxen |
| 07/03/2002 | EP1063978A4 Method of treating neuroma pain |
| 07/03/2002 | EP0563345B1 Novel 4-arylpiperazines and 4-arylpiperidines |
| 07/03/2002 | CN1357003A 类固醇衍生物 Steroid derivatives |
| 07/03/2002 | CN1357002A Compositions for treating inflammatory response |
| 07/03/2002 | CN1357000A Water soluble prodrugs of hindered alcohols or phenols |
| 07/03/2002 | CN1356996A Benzofurane derivatives |
| 07/03/2002 | CN1356995A Substituted benzimidazole |
| 07/03/2002 | CN1356987A Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds |
| 07/03/2002 | CN1356986A Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical prepns. comprising them |
| 07/03/2002 | CN1356984A Neurotrophin protentiators |
| 07/03/2002 | CN1356916A Use of fluorinated triazoles for treating pain and affective or attention disorders |
| 07/03/2002 | CN1356911A Method for treatment of fibrosis using antagonist of integrin alpha-4 subunit |
| 07/03/2002 | CN1356907A Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/03/2002 | CN1356906A Therapeutic methods and compsns. for treatment of in paired interpersonal and behavioral disorders |
| 07/03/2002 | CN1356903A Synthesis and crystallization of piperazine ring-contg. compounds |
| 07/03/2002 | CN1356902A IL-8 receptor antagonists |
| 07/03/2002 | CN1356900A MAG expression promoters |
| 07/03/2002 | CN1356897A Method of treating sleep apnoea |
| 07/03/2002 | CN1356136A Chinese medicine for treating epilepsy |
| 07/03/2002 | CN1356110A Sobering-up liquid |
| 07/03/2002 | CN1356104A Antalgic method by general medicine application |
| 07/02/2002 | US6414157 Compounds having high affinity for 5-ht1b and 5-ht1c serotonin receptor; antidepressants |
| 07/02/2002 | US6414154 Tetraisoquinoline derivatives as modulators of dopamine D3 receptors |
| 07/02/2002 | US6414153 1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease |
| 07/02/2002 | US6414147 2-amino-9-alkylpurines: GABA brain receptor ligands |
| 07/02/2002 | US6414144 Such as (2s)-(rel-7br,10ar)-2-methyl-1,2,3,4,8,9,10,10a-octahydro-7bh -cyclopenta(b)(1,4)diazepino(6,7,1-hi)indole; for treatment of obesity |
| 07/02/2002 | US6414128 Leptin ligand binding; medical diagnosis, therapy, agonists, and antagonists; genetic engineering |
| 07/02/2002 | US6414030 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptors blockers |
| 07/02/2002 | US6414025 Rheumatic disorders; antiinflammatory agents; autoimmune diseases |
| 07/02/2002 | US6414013 Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| 07/02/2002 | US6414011 Central nervous system disorders |
| 07/02/2002 | US6414009 Cardiovascular disorders; anticoagulants |
| 07/02/2002 | US6413991 Antidiabetic agents; dietetics |
| 07/02/2002 | US6413989 Piperidinylmethyloxazolidinone derivative |
| 07/02/2002 | US6413986 [1-indanon-2-yl]methylpiperidines |
| 07/02/2002 | US6413985 Selective antagonists for the strychnine insensitive glycine binding site associated with the nmda receptor complex. |
| 07/02/2002 | US6413982 4-substituted quinoline derivatives |
| 07/02/2002 | US6413978 Basic derivatives of benz[e] isoindol-1-ones and pyrrolo[3,4-c] quinolin-1-ones with 5-HT3-antagonistic activity, their preparation and their therapeutic use |
| 07/02/2002 | US6413977 Chromeno[4,3,2-DE]isoquinolines as potent dopamine receptor ligands |
| 07/02/2002 | US6413975 Purine derivatives having phosphodiesterase iv inhibition activity |
| 07/02/2002 | US6413966 Serotonergic and central dopaminergic activity; affinity for 5ht1a and 5ht2 serotonin and d2 dopamine receptors; atypical antipsychotics; schizophrenia |
| 07/02/2002 | US6413963 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease |
| 07/02/2002 | US6413959 Neurokinin(tachykinin) antagonists |
| 07/02/2002 | US6413958 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-barr virus; enzyme inhibitors |
| 07/02/2002 | US6413956 Substituted 4-oxo-quinoline-3-carboxamides |
| 07/02/2002 | US6413948 Central nervous system disorders |
| 07/02/2002 | US6413940 Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| 07/02/2002 | US6413930 Controlling eye movement |
| 07/02/2002 | US6413764 Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413719 KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies |
| 07/02/2002 | US6413507 Modified polyether |
| 07/02/2002 | CA2194984C 4-indole derivatives as serotonin agonists and antagonists |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 07/02/2002 | CA2018149C Aminoketone compounds |
| 06/27/2002 | WO2002050289A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050115A1 Modified tachykinin receptors |
| 06/27/2002 | WO2002050105A1 Novel compounds |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050085A1 A new process for preparing fused 1,2,4-thiadiazine derivatives |
| 06/27/2002 | WO2002050079A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | WO2002050078A1 Novel substituted imidazotriazinones as pde ii-inhibitors |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | WO2002050067A2 Pharmaceutical heterocyclic compounds |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050063A1 New process |
| 06/27/2002 | WO2002050062A2 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors |
| 06/27/2002 | WO2002050057A1 Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders |
| 06/27/2002 | WO2002050044A1 Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050013A1 Carboxylic acid compound having cyclopropane ring |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049667A2 Vaccine for treating nicotine addiction |
| 06/27/2002 | WO2002049663A2 Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
| 06/27/2002 | WO2002049662A2 Use of the prion protein (prp) for suppression of bax-mediated apoptosis |
| 06/27/2002 | WO2002049652A1 Method of treatment |
| 06/27/2002 | WO2002049647A2 Novel therapeutic use of a thienylcyclohexylamine derivative |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049644A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders |
| 06/27/2002 | WO2002049643A1 Treatment of depression |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049630A2 Method for preventing or treating pain by administering an endothelin antagonist |
| 06/27/2002 | WO2002049629A2 Methods for reducing chronic stress in mammals |
| 06/27/2002 | WO2002049628A2 Methods of treating anxiety disorders |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |